Comment on ‘Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?’ Maillart et al.

Abstract

Get full access to this article

View all access options for this article.

References

Rudick

Stuart

Calabresi

. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911–923.

Polman

O’Connor

Havrdova

. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

Miller

Khan

Sheremata

. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15–23.

Horga

Castillo

Rio

. [An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis]. Rev Neurol 2011; 52: 321–330.

Bloomgren

Richman

Hotermans

. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880.

Vellinga

Castelijns

Barkhof

. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70: 1150–1151.

Plavina

Subramanyam

Bloomgren

. Use of JC virus antibody index to stratify risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosis (oral communication). 23rd Meeting of the European Neurological Society. 8–11 June, 2013. Barcelona, Spain.

Kappos

Comi

Montalban

. Disease control and safety in relapsing-remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: A 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO). Oral communication at ECTRIMS meeting 2013. 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2–5 October, 2013. Copenhagen, Denmark.

Singer

. Initiating oral fingolimod treatment in patients with multiple sclerosis. Ther Adv Neurol Disord 2013; 6: 269–275.